Toronto, ON, July 11, 2013 – iGan Partners is pleased to announce an investment in MolecuLight Inc. a company specializing in point-of-care diagnostic imaging.
MolecuLight’s first commercial application, PRODIGI , is a handheld optical imaging device using auto-fluorescence to instantly detect, analyze and quantify bacterial loads. More than 5 years of clinical trial validation show that PRODIGI will bring very significant improvements to the woundcare industry. PRODIGI allows for guided debridement and real-time quantitative monitoring, which results in improved patient outcomes and a more efficient use of clinical resources. Moleculight’s technology platform will also have further applications in other medical and non-medical markets.
MolecuLight has developed a revolutionary portable handheld optical imaging device for point-of-care wound analysis. The device allows for visual detection of bacteria, procedural guidance, assessment of viable vs. non-viable tissues, and the quantification, tracking and documentation of bacterial load.